3 Things You Should Know About Early Treatment Intervention for TED

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

Thyroid eye disease (TED), a rare autoimmune condition, can be sight-threatening, debilitating, and disfiguring, severely impacting patients’ quality of life and daily functioning. Traditional management approaches for TED have centered on immunomodulatory therapy and surgical interventions. In January 2020, the US Food and Drug Administration (FDA) approved teprotumumab, the first therapy specifically indicated for TED. As treatment options evolve, there is an increasing need for a patient-centered, multidisciplinary approach, which is essential to address individual patient needs throughout the disease course.

This PER On Air Ophthalmology Times podcast provides an in-depth review of some of the key highlights from a satellite symposium that took place at the Envision Summit 2025 meeting in February 2025.This unique and engaging activity focuses on the practical aspects of managing patients with thyroid eye disease, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Amgen, Inc.

Faculty:

Sara T. Wester, MD, FACS

Professor of Clinical Ophthalmology
Oculofacial Plastic and Reconstructive Surgery
Orbital Surgery and Oncology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, FL

Disclosures: Grant/Research Support: Amgen, Argenx, Horizon Therapeutics, Immunovant, Tourmaline Bio; Consultant: Lassen Therapeutics; Adviser: Amgen, Immunovant

Cecelia Koetting, OD

Assistant Professor
Department of Ophthalmology
University of Colorado School of Medicine
Anschutz Medical Campus
Denver, CO

Disclosures: Grant/Research Support: Johnson & Johnson, Ocular Therapeutix; Consultant: Alcon, Aldeyra Therapeutics, Allergan/AbbVie, Avellino, Azura Ophthalmics, Bausch + Lomb, Blinkjoy, Bruder, Claris Bio, Dompé, Eyevance/Santen Pharmaceutical, Glaukos, KALA BIO, Myze, Orasis Pharmaceuticals, Oyster Point Pharma/Viatris, RVL Pharmaceuticals, Sight Sciences, Tarsus Pharmaceuticals, Thea, Topcon, Twenty/Twenty Therapeutics, Verséa, Visus Therapeutics

Sophie Liao, MD

Robert H. Bell Endowed Chair in Ophthalmology
Associate Chief Medical Officer of Ambulatory Services
UCHealth University of Colorado Hospital
Associate Professor, Division of Oculofacial Plastic and Reconstructive Surgery
Department of Ophthalmology
University of Colorado School of Medicine
Aurora, CO

Disclosures: Dr Liao has no relevant financial relationships with ineligible companies to disclose.

Jennifer Murdock, MD

CEO/Owner
Jennifer Murdock, MD, PLLC
Miami, FL

Disclosures: Speakers Bureau: Alastin Skincare, Evolus.

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

PER® mitigated all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Release Date

May 30, 2025

Expiration Date

May 30, 2026